Anti-fibrogenic strategies and the regression of fibrosis.
about
Controversies over the Epithelial-to-Mesenchymal Transition in Liver FibrosisBone marrow-derived fibrocytes contribute to liver fibrosisCellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat modelMolecular mechanism and treatment of viral hepatitis-related liver fibrosis.Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomesContribution of bone marrow-derived fibrocytes to liver fibrosisProtection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stressAndrographis paniculata leaf extract prevents thioacetamide-induced liver cirrhosis in ratsNoninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.Cardiac fibroblast in development and wound healing.Value of MR diffusion imaging in hepatic fibrosis and its correlations with serum indices.Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes.Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in ratsAntagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model.Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis CAngiotensin II facilitates fibrogenic effect of TGF-β1 through enhancing the down-regulation of BAMBI caused by LPS: a new pro-fibrotic mechanism of angiotensin II.Spleen dynamic contrast-enhanced magnetic resonance imaging as a new method for staging liver fibrosis in a piglet model.Pathobiochemical signatures of cholestatic liver disease in bile duct ligated mice.Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defencecAMP and Epac in the regulation of tissue fibrosis.Chronic restraint stress decreases the repair potential from mesenchymal stem cells on liver injury by inhibiting TGF-β1 generation.Novel insight into mechanisms of cholestatic liver injury.Reversibility of Stricturing Crohn's Disease-Fact or Fiction?Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.Experimental models of liver fibrosisHDAC inhibitors in experimental liver and kidney fibrosis.Liver Injury Assessment by Vetscan VS2 Analyzer and Most Frequently Used ALT/GTP Reagent.Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.Contribution of Myofibroblasts of Different Origins to Liver FibrosisReversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies.Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.Loss of lysosomal membrane protein NCU-G1 in mice results in spontaneous liver fibrosis with accumulation of lipofuscin and iron in Kupffer cells.Anti-fibrosis effects of Huisheng oral solution in CCl4-induced hepatic fibrosis in rat.Quantitative Proteomic analysis on Activated Hepatic Stellate Cells reversion Reveal STAT1 as a key regulator between Liver Fibrosis and recovery.A New Oleanolic Acid Derivative against CCl₄-Induced Hepatic Fibrosis in Rats.Review article: the reversibility of cirrhosis.
P2860
Q26771108-3E4DFE3B-1EFE-4141-903F-DE3C97C9D46CQ27021576-552DE794-FC4D-4218-BD11-4640CD8AF514Q27027703-47EC7174-C60A-4486-939F-569B6128F7ADQ27309869-9DF2AE28-27C6-45FC-B69C-EB9520745797Q27692609-A53F72AD-E3D8-405F-8199-0B97693866ABQ28081216-71F23419-249C-4083-87F1-F01AA3EA888EQ28083363-D724E36A-DAF2-43A0-8648-992BAE691F3CQ28539856-8C24C9BF-3E08-43D2-8845-968060EEEC07Q28543537-84342E2E-3951-475C-A8CE-80A0005E108FQ30397191-AEFE498C-C2A8-4764-A11B-739DD256762BQ33639215-531DA53A-ED99-4CC9-A46B-233594A42A1CQ33801435-F7F6C8C1-3BD6-494C-A8CE-4F2B3633F8E9Q33881786-2C5163CF-980B-4DDE-86C5-59245F6D3C19Q34414756-11F4AA09-37FB-483F-836F-A17344BF890DQ34415930-C92A268E-A22C-430A-833A-5E93FA45DE0AQ34532528-AC78F592-D3DA-4F47-8F93-A1661FE71BAEQ34747195-77B8C5AE-C0EA-4DF7-8DE3-F73FE55A81CDQ35025282-7F285FA7-1214-4CBE-86B3-0BB90123D964Q35078154-41450680-B465-494D-9C15-B8D130B25B1CQ35847494-B4FC809F-99C9-401C-9BF8-6DADD7337B47Q35940373-3B432BA8-CC8C-4512-BE49-33E00F1801CFQ36159130-221643AD-3246-4421-B8B4-4ED15F85A6ECQ36179620-B03C8E5C-4CF1-46FA-A6FC-98AF69A8016AQ36285749-7E71B085-5057-404B-A5A9-43C62890B2C2Q36373253-DD7DCEF3-8C84-481E-BC1B-840FF48EFBC3Q36393781-806EC071-2EF7-4DFD-880A-D16A41C0FC4EQ36442525-8620BE77-8E67-47B0-A4FB-1BBABAB543CDQ36588493-137A5F9E-2003-4F34-99DC-18BE3C635C2CQ36962271-A2EDB8FA-A547-4A0B-A5B1-9203B9CA540AQ37029796-3D215BC3-08F4-438E-B21E-A2F45BCE751DQ37128332-586D14F6-A6D6-4631-A722-CF54215564AAQ37132266-5BFEAD41-784B-4F76-AE9D-C52BE9515A31Q37193215-53DA36EC-3F60-4CD8-9CED-D98D2CDE7043Q37355850-C390C51C-D997-49E1-93A6-EB3165FCD133Q37363773-3072A179-94B5-49D6-B396-1538BFE3D74DQ37621079-FF4EB810-8151-4100-B3B7-CD3A6D913CFDQ37703563-A4552040-5638-4E94-944C-0E680ACFB2AAQ37713034-76FA289F-A312-46BC-A385-C9E22E4CE507Q37729132-FFE8EAE2-425E-4BC9-A109-39929081E9EBQ38042443-6CA75B32-6B19-4240-A794-2AFED221C303
P2860
Anti-fibrogenic strategies and the regression of fibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-fibrogenic strategies and the regression of fibrosis.
@en
Anti-fibrogenic strategies and the regression of fibrosis.
@nl
type
label
Anti-fibrogenic strategies and the regression of fibrosis.
@en
Anti-fibrogenic strategies and the regression of fibrosis.
@nl
prefLabel
Anti-fibrogenic strategies and the regression of fibrosis.
@en
Anti-fibrogenic strategies and the regression of fibrosis.
@nl
P2860
P1476
Anti-fibrogenic strategies and the regression of fibrosis.
@en
P2093
Tatiana Kisseleva
P2860
P304
P356
10.1016/J.BPG.2011.02.011
P577
2011-04-01T00:00:00Z